RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:NewsYou make some good points, you always have. And if you had been around in this story as long as i have, you would know that i have been a harsh critic of PL's overoptimism. Its driven me crazy. Particularly as it applies to the promise of BD licensing deals. I have been pressing hard for a long time to hire a prominent Investment Bank with a strong mandate to help strategize and monetize some of their IP. Narrow the focus of the business and focus on some
of the great potential that they have created, and do it in a professional manner in a dependable time frame
i think this stuff is happenning. They have a sub board of very experienced industry execs and solid businessmen who's sole mandate is to form the IP monetization strategy, and i suspect they are finally making good progress. In fact i know that the execs were meeting with IB's and analysts in NY last week. Two huge catalysts from a BD standpoint are the imminent FDA IND approval of 4050, as well as the expanded 24 weeks Allstrom Trial data. These are major needle movers for BD deal valuation and competitove tensions
Layer all that in with the overall de risking thats coming from PG Approval and product launch, the virtual certainty of a monetizeable PD Voucher and then subsequent orphan drug PPPs pipeline announcements and launch, US awareness and visibility will continue to grow, and the smart money will continue
to roll in. Eventually shrinking the CDA /US valuation gap
i am not nearly as focussed on the very near term. I would be surprised if anything major is lined up for monday, that would be a bonus...but i do think October has the prospect
to be one of the most exciting months in the history of this company, and i cerrainly dont think the current semtiment or stock price is reflecting that, nor is it reflecting the value build that will happen over the next year as risk is systematically removed